Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• SALL4 is a transcription factor crucial for stem cell self-renewal and maintaining pluripotency.
• Dysregulation of SALL4 is implicated in leukemogenesis, particularly through its influence on leukemic stem cells.
• Understanding SALL4 expression patterns in myeloid leukemias is vital for prognostic assessment.

Purpose of the Study:

• To investigate the gene expression profile of SALL4 in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) across different disease stages.
• To evaluate the prognostic significance of SALL4 expression in AML and CML patients.
• To correlate SALL4 expression levels with disease progression and patient survival outcomes.

Main Methods:

• Quantitative real-time PCR was employed to measure SALL4 gene expression.
• The study included 106 leukemia patients (54 AML, 52 CML) and 21 non-malignant controls.
• Patients were categorized by leukemia type, phase (de novo, complete remission, chronic phase, advanced phase), and molecular response.

Main Results:

• SALL4 gene expression was significantly elevated in de novo AML, AML in complete remission (CR), and chronic phase CML (CP) compared to controls.
• Elevated SALL4 expression in de novo AML patients correlated with poorer disease-free survival (DFS).
• High SALL4 expression was most prevalent in the chronic phase of CML.

Conclusions:

• SALL4 plays a role in the pathogenesis of myeloid leukemias.
• High SALL4 expression is a potential biomarker for poor prognosis in AML patients.
• Further research into SALL4's role in CML progression is warranted.